Jacklyn N. Hellwege

Vanderbilt University Medical Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (6)

Identification of drug-repurposing targets with genetic and biological support is an economically and temporally efficient strategy for improving treatment of diseases. We employed a cross-disciplinary approach to identify potential treatments for metabolic dysfunction associated steatotic liver disease (MASLD) using humans as a model organism. We identified 212 putative causal genes associated with MASLD using data from a large multi-ancestry genetic association study, of which 158 (74.5%) are novel. From this set we identified 57 genes that encode for druggable protein targets, and where the effects of increasing genetically predicted gene expression on MASLD risk align with the function of that drug on the protein target. These potential targets were then evaluated for evidence of efficacy using Mendelian randomization, pathway analysis, and protein structural modeling. Using these approaches, we present compelling evidence to suggest activation of FADS1 by icosopent ethyl as well as S1PR2 by fingolimod could be promising therapeutic strategies for MASLD.

Year:

2025

Keloids are raised scars that grow beyond original wound boundaries, resulting in pain and disfigurement. Reasons for keloid development are not well-understood, and current treatment options are limited. Keloids are more likely to occur in darker-skinned individuals of African and Asian descent than in Europeans. We performed a genome-wide association study (GWAS) examining keloid risk across and within continental ancestry groups, incorporating 7,837 cases and 1,593,009 controls. We detected 21 novel independent loci in the multi-ancestry analysis, including several previously associated with fibroproliferative disorders. Heritability estimates were 6%, 21%, and 34% for the European, East Asian, and African ancestry analyses, respectively. Genetically predicted gene expression and colocalization analyses identified 27 gene-tissue pairs, including nine in skin and fibroblasts. Pathway analysis implicated integrin signaling and upstream regulators involved in cancer, fibrosis, and sex hormone signaling. This investigation nearly quintuples the number of keloid-associated risk loci, illuminating biological processes in keloid pathology.

Year:

2025

While most pregnancies are affected by nausea and vomiting, hyperemesis gravidarum (HG) is at the severe end of the clinical spectrum and is associated with dehydration, undernutrition, and adverse maternal, fetal, and child outcomes. Herein we performed a multi-ancestry genome-wide association study (GWAS) of severe nausea and vomiting of pregnancy of 10,974 cases and 461,461 controls across European, Asian, African, and Latino ancestries. We identified ten significantly associated loci, of which six were novel ( SLITRK1 , SYN3 , IGSF11 , FSHB , TCF7L2 , and CDH9), and confirmed previous genome-wide significant associations with risk genes GDF15 , IGFBP7 , PGR , and GFRAL . In a spatiotemporal analysis of placental development, GDF15 and TCF7L2 were expressed primarily in extra villous trophoblast, and using a weighted linear model of maternal, paternal, and fetal effects, we confirmed opposing effects for GDF15 between maternal and fetal genotype. Conversely, IGFBP7 and PGR were primarily expressed in developing maternal spiral arteries during placentation, with effects limited to the maternal genome. Risk loci were found to be under significant evolutionary selection, with the strongest effects on nausea and vomiting mid-pregnancy. Selected loci were associated with abnormal pregnancy weight gain, pregnancy duration, birth weight, head circumference, and pre-eclampsia. Potential roles for candidate genes in appetite, insulin signaling, and brain plasticity provide new pathways to explore etiological mechanisms and novel therapeutic avenues.

Year:

2024

Gene-gene (GxG) interactions play an important role in human genetics, potentially explaining part of the “missing heritability” of polygenic traits and the variable expressivity of monogenic traits. Many GxG interactions have been identified in model organisms through experimental breeding studies, but they have been difficult to identify in human populations. To address this challenge, we applied two complementary variance QTL (vQTL)-based approaches to identify GxG interactions that contribute to human blood traits and blood-related disease risk. First, we used the previously validated genome-wide scale test for each trait in ∼450,000 people in the UK Biobank and identified 4 vQTLs. Genome-wide GxG interaction testing of these vQTLs enabled discovery of novel interactions between (1) CCL24 and CCL26 for eosinophil count and plasma CCL24 and CCL26 protein levels and (2) HLA-DQA1 and HLA-DQB1 for lymphocyte count and risk of celiac disease, both of which replicated in ∼140,000 NIH All of Us and ∼70,000 Vanderbilt BioVU participants. Second, we used a biologically informed approach to search for vQTL in disease-relevant genes. This approach identified (1) a known interaction for hemoglobin between two pathogenic variants in HFE which cause hereditary hemochromatosis and alters risk of cirrhosis and (2) a novel interaction between the JAK2 46/1 haplotype and a variant on chromosome 14 which modifies platelet count, JAK2 V617F clonal hematopoiesis, and risk of polycythemia vera. This work identifies novel disease-relevant GxG interactions and demonstrates the utility of vQTL-based approaches in identifying GxG interactions relevant to human health at scale.

Year:

2024

The burden of comorbidities in those with uterine fibroids compared to those without fibroids is understudied. We performed a phenome-wide association study to systematically assess the association between fibroids and other conditions. Vanderbilt University Medical Center’s Synthetic Derivative and Geisinger Health System Database, two electronic health record databases, were used for discovery and validation. Non-Hispanic Black and White females were included. Fibroid cases were identified through a previously validated algorithm. Race-stratified and cross-ancestry analyses, adjusting for age and body mass index, were performed before significant, validated results were meta-analyzed. There were 52,200 and 26,918 (9,022 and 10,232 fibroid cases) females included in discovery and validation analyses. In cross-ancestry meta-analysis, 389 conditions were associated with fibroid risk with evidence of enrichment of circulatory, dermatologic, genitourinary, musculoskeletal, and sense organ conditions. The strongest associations within and across racial groups included conditions previously associated with fibroids. Numerous novel diagnoses, including cancers in female genital organs, were tied to fibroid status. Overall, individuals with fibroids had a marked increase in comorbidities compared to those without fibroids. This novel approach to evaluate the health context of fibroids highlights the potential to understand fibroid etiology through studying common biology of comorbid diagnoses and through disease networks.

Year:

2024

Year:

2022

Collaborators (20)

Nicholas Mancuso

Associate Professor

University of Southern California

UNITED STATES
View details

David van Heel

Professor

Queen Mary University of London

UNITED KINGDOM
View details

Julia Zollner

NIHR Academic Clinical Lecturer

University College London

UNITED KINGDOM
View details

Yuan Luo

Chief AI Officer and Associate Professor

Northwestern University

UNITED STATES
View details

Digna R. Velez Edwards

Vanderbilt University Medical Center

UNITED STATES
View details

Adam Bress

Research Assistant Professor

University of Utah

UNITED STATES
View details

Atlas Khan

Assistant professor

Columbia University

UNITED STATES
View details

Marijana Vujkovic

Research Assistant Professor

University of Pennsylvania

UNITED STATES
View details

Michael Levin

Cardiologist

Corporal Michael J. Crescenz VA Medical Center

UNITED STATES
View details

Megan M Shuey

Vanderbilt University Medical Center

UNITED STATES
View details

Marc Vaudel

Professor at University of Bergen

University of Bergen

NORWAY
View details

Triin Laisk

Associate Professor

University of Tartu

ESTONIA
View details

Jeewoo Kim

Vanderbilt University

UNITED STATES
View details

Dipender Gill

Imperial College London

UNITED KINGDOM
View details

Jens Meiler

Vanderbilt University

UNITED STATES
View details

Todd Edwards

Assistant Professor

Vanderbilt University

UNITED STATES
View details

Sarah Finer

Professor of Clinical Diabetes

Queen Mary University of London

UNITED KINGDOM
View details

Marlena Fejzo

Assistant Professor

University of Southern California

UNITED STATES
View details

Alexander Bick

Assistant Professor

Vanderbilt University

UNITED STATES
View details

Kyong-Mi Chang

Professor of Medicine & Associate Chief of Staff for R&D

University of Pennsylvania

UNITED STATES
View details